Systematic trial for evaluating docetaxel in a human prostate cancer cell DU145 xenograft model

8Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

The inhibitory activities of docetaxel at a wide range of doses (0.1-10 mg/kg; subcutaneously (s.c.), once/week) in nude mice bearing a human prostate cancer cell (DU145), xenograft model with implantation of DU145 cells or a DU145 solid tumor were examined. This systematic trial demonstrated that (i) docetaxel was more effective in the xenograft model formed by implantation of DU145 cells than in the solid DU145 tumor; (ii) administration of 2.5 mg/kg docetaxel was the critical dose because inhibitory activities were not observed at 2.5 mg/kg, while they were noted at 5 mg/kg and 10 mg/kg in both implantation approaches; (iii) edema-like effects (plump body shape and legs) were observed in both groups at 2.5 mg/kg and the tumor sizes, often increased by blood plasma and other fluids, as well as body weights were higher than at other doses; and (iv) suppression of body weight gain was observed at 10 mg/kg docetaxel.

Cite

CITATION STYLE

APA

Mabuchi, M., Ueda, M., Yoshida, Y., Horiike, K., Yamaoka, K., Nakao, S., … Tanaka, A. (2017). Systematic trial for evaluating docetaxel in a human prostate cancer cell DU145 xenograft model. Anticancer Research, 37(4), 1665–1676. https://doi.org/10.21873/anticanres.11497

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free